Free Trial

Stock Price Targets and Analyst Ratings

CompanyActionBrokerageAnalystCurrent PricePrice TargetRatingDetails
Apellis Pharmaceuticals, Inc. stock logo
APLS
Apellis Pharmaceuticals
Initiated byMorgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
$27.49
-5.2%
$31.00Equal Weight
Broadridge Financial Solutions, Inc. stock logo
BR
Broadridge Financial Solutions
Initiated byUBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
$225.39
+0.2%
$250.00Neutral
The Ensign Group, Inc. stock logo
ENSG
The Ensign Group
Initiated byUBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
$144.66
+0.1%
$175.00Buy
4D Molecular Therapeutics, Inc. stock logo
FDMT
4D Molecular Therapeutics
Initiated byMorgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
$8.41
-3.0%
$8.00Underweight
GE Vernova Inc. stock logo
GEV
GE Vernova
Initiated byWells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
$342.77
+0.8%
$385.00Overweight
Merus stock logo
MRUS
Merus
Initiated byThe Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
$42.93
-1.3%
$73.00Buy
New Year, New Opportunity! 2 AI Stocks Under $10 Ready to Soar (Ad)

As we step into 2025, artificial intelligence (AI) stocks continue to dominate headlines, and now is the perfect moment to position yourself for the coming year’s potential. Our latest research has uncovered two must-buy AI stocks currently trading under $10/share – an affordable entry with promising growth potential. These stocks are flying under the radar, but it’s only a matter of time before they gain mainstream attention.

👉 Click here to access your FREE report now!

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Thursday at 07:44 AM ET.